 |
245 Diseases |  |
393 Trials |
|
393 Trials |  |
11527 News |  |
| «12...134135136137138139140141142143144145146 |
- ||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 18, 2011
P3, N=939, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab (clinicaltrials.gov) - Sep 15, 2011
P2, N=303, Completed, Sponsor: Centre Francois Baclesse
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
New P1 trial, Metastases: Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib (clinicaltrials.gov) - Sep 8, 2011
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas (clinicaltrials.gov) - Sep 8, 2011
P2, N=36, Completed, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2/3 trial, Metastases: EAGLE: Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (clinicaltrials.gov) - Sep 1, 2011
P2/3, N=243, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Enrollment open, IO biomarker, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Sep 1, 2011
P1, N=30, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed: Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - Aug 31, 2011
P2, N=100, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, linsitinib (ASP7487) / Sling Therap
New P2 trial, Metastases: Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Aug 30, 2011
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
- |||| Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Metastases: Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer (clinicaltrials.gov) - Aug 25, 2011
P2, N=79, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
New P1 trial, IO biomarker, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Aug 18, 2011
P1, N=30, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, FDG PET, Metastases: 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx (clinicaltrials.gov) - Aug 16, 2011
P2, N=30, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 10, 2011
P2, N=65, Recruiting, Sponsor: New Mexico Cancer Care Alliance
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients (clinicaltrials.gov) - Aug 9, 2011
P2, N=69, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC) (clinicaltrials.gov) - Aug 8, 2011
P2, N=27, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed N=36 --> 27
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Monotherapy, Surgery: CHIRON: Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery (clinicaltrials.gov) - Aug 8, 2011
P1/2, N=34, Completed, Sponsor: Cliniques universitaires Saint-Luc- Universit
N=36 --> 27 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer (clinicaltrials.gov) - Aug 8, 2011
P1, N=46, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Aug 7, 2011
P2, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center